Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
The following slide deck was published by Ipsen S.A. ADR in conjunction with this Read more ...
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
– Review of NAPOLI-1 Data Evaluated Impact of Protocol-defined Dose Modifications Used to Manage Adverse Events on Overall Survival in Patients Treated with ONIVYDE ® – Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, (Euronext: IPN; ADR: IPSEY), today an...
Exelixis (NASDAQ: EXEL ) +2.5% after-hours after announcing with partner Ipsen ( OTCPK:IPSEF , OTCPK:IPSEY ) that its cabozantinib cancer drug achieved its primary endpoint in a late-stage study and will be submitted to the FDA before the end of the quarter. More news on: Exelixis, In...
Pivotal phase 3 CELESTIAL trial results, including additional subset analyses, to be presented during oral session on Friday, January 19 at the 2018 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) In line with and in collaboration with our pa...
– Pivotal phase 3 CELESTIAL trial results, including additional subset analyses, to be presented during oral session on Friday, January 19 at the 2018 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO-GI) – – Exelixis to sub...
Ipsen to co-host financial community briefing to discuss data presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that irinotecan liposome injection (Onivyde ® ), cab...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Richard Paulson as Executive Vice-President and Chief Executive Officer of Ipsen North America, responsible for all commercial operations throughout the region. Mr Paulson will assume oversight of all a...
The following slide deck was published by Ipsen S.A. ADR in conjunction with this Read more ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1 st , 2018, in accordance with Articles L221-32-2 and D221-113-5 of
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...